ECSP034474A - Nuevo tratamiento - Google Patents

Nuevo tratamiento

Info

Publication number
ECSP034474A
ECSP034474A ECSP034474A ECSP034474A EC SP034474 A ECSP034474 A EC SP034474A EC SP034474 A ECSP034474 A EC SP034474A EC SP034474 A ECSP034474 A EC SP034474A
Authority
EC
Ecuador
Prior art keywords
new treatment
antigen
vaccines
vaccine
hepatitis
Prior art date
Application number
Other languages
English (en)
Inventor
Heyder Koen De
Opstel Omer Van
Michelle Serantoni
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of ECSP034474A publication Critical patent/ECSP034474A/es

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Este invento se refiere a un procedimiento para la producción de un antigeno de la hepatitis B adecuado para uso en una vacuna, comprendiendo el procedimiento la purificación del antigeno en presencia de cisteína y a vacunas que comprenden tales antígenos.
ECSP034474 2001-01-18 2003-02-07 Nuevo tratamiento ECSP034474A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds

Publications (1)

Publication Number Publication Date
ECSP034474A true ECSP034474A (es) 2003-08-29

Family

ID=9907070

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP034474 ECSP034474A (es) 2001-01-18 2003-02-07 Nuevo tratamiento

Country Status (2)

Country Link
EC (1) ECSP034474A (es)
GB (1) GB0101334D0 (es)

Also Published As

Publication number Publication date
GB0101334D0 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
UY26882A1 (es) Nuevo tratamiento
ATE542829T1 (de) Impfstoff
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
NO20025838L (no) Antigeniske polypeptider
ATE350057T1 (de) Impfstoffzusammesetzung
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
AR061894A1 (es) Vacunas para malaria
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DK1259259T3 (da) Mucosal adjuvansformulering
CR11307A (es) Vacunas
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
WO2003066094A3 (en) Hepatitis b vaccines
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ECSP034474A (es) Nuevo tratamiento
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
UY31574A1 (es) Vacunas contra la malaria
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
CO2019000942A2 (es) Composición y uso de un péptido